AI assistant
IMMUTEP LIMITED — Capital/Financing Update 2012
Apr 12, 2012
65122_rns_2012-04-12_d94e7aec-53b2-4554-a874-ee55249ac0e4.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ASX/Media Release (Code: ASX:PRR, NASDAQ:PBMD) 13th April 2012
==> picture [215 x 40] intentionally omitted <==
PRIMA BIOMED TO LIST ON NASDAQ ON APRIL 16
Australian healthcare company Prima BioMed Ltd (ASX: PRR, NASDAQ:PBMD) (Prima) is pleased to announce that it will commence trading on the NASDAQ Stock Market (NASDAQ) of American Depositary Receipts (ADR), on Monday, April 16, 2012 U.S. Eastern Time.
Upon listing on the NASDAQ, the Company will have dual listings of its securities on both the Australian Securities Exchange (ASX) and NASDAQ.
Every one ADR will represent 30 ordinary fully paid shares. Prima’s NASDAQ listing is a Level II ADR compliance listing, and will be managed by Bank of New York Mellon.
Bank of New York Mellon will be Prima’s deposit agent for converting the Company’s common shares into ADRs. Deutsche Bank Securities Inc., Noble Financial Capital Markets and Aegis Capital are market makers for Prima in the United States.
A registration statement relating to the ADR’s has been filed with, and declared effective by, the U.S. Securities and Exchange Commission.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
ENDS
About Prima BioMed
Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy.
For further information please contact:
Martin Rogers Mr James Moses Chief Executive Officer Investor and Media Relations Prima BioMed Mandate Corporate Ph: +61 2 9276 1224 Ph: +61 (0) 420 991 574 E: [email protected] E: [email protected]
US Investor Relations
Ms Kathy Galante Investor Relations Burns McClellan, Inc Ph: +1 (212) 213-0006 E: [email protected]
Prima BioMed Ltd , Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 9276 1284 ABN: 90 009 237 889